These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20439987)

  • 1. NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.
    Krejci P; Murakami S; Prochazkova J; Trantirek L; Chlebova K; Ouyang Z; Aklian A; Smutny J; Bryja V; Kozubik A; Wilcox WR
    J Biol Chem; 2010 Jul; 285(27):20644-53. PubMed ID: 20439987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage.
    Krejci P; Salazar L; Kashiwada TA; Chlebova K; Salasova A; Thompson LM; Bryja V; Kozubik A; Wilcox WR
    PLoS One; 2008; 3(12):e3961. PubMed ID: 19088846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.
    Meyer AN; McAndrew CW; Donoghue DJ
    Cancer Res; 2008 Sep; 68(18):7362-70. PubMed ID: 18794123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia.
    Matsushita M; Kitoh H; Ohkawara B; Mishima K; Kaneko H; Ito M; Masuda A; Ishiguro N; Ohno K
    PLoS One; 2013; 8(12):e81569. PubMed ID: 24324705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition.
    St-Germain JR; Taylor P; Tong J; Jin LL; Nikolic A; Stewart II; Ewing RM; Dharsee M; Li Z; Trudel S; Moran MF
    Proc Natl Acad Sci U S A; 2009 Nov; 106(47):20127-32. PubMed ID: 19901323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
    Qing J; Du X; Chen Y; Chan P; Li H; Wu P; Marsters S; Stawicki S; Tien J; Totpal K; Ross S; Stinson S; Dornan D; French D; Wang QR; Stephan JP; Wu Y; Wiesmann C; Ashkenazi A
    J Clin Invest; 2009 May; 119(5):1216-29. PubMed ID: 19381019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
    Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
    Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.
    Foldynova-Trantirkova S; Wilcox WR; Krejci P
    Hum Mutat; 2012 Jan; 33(1):29-41. PubMed ID: 22045636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins do not inhibit the FGFR signaling in chondrocytes.
    Fafilek B; Hampl M; Ricankova N; Vesela I; Balek L; Kunova Bosakova M; Gudernova I; Varecha M; Buchtova M; Krejci P
    Osteoarthritis Cartilage; 2017 Sep; 25(9):1522-1530. PubMed ID: 28583899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribozyme cleavage leads to decreased expression of fibroblast growth factor receptor 3 in human multiple myeloma cells, which is associated with apoptosis and downregulation of vascular endothelial growth factor.
    Qian S; Somlo G; Zhou B; Zhu L; Mi S; Mo X; Cheung EM; Qiu W; Lin RJ; Rossi J; Holtz M; Chu P; Yen Y
    Oligonucleotides; 2005; 15(1):1-11. PubMed ID: 15788896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma.
    Paterson JL; Li Z; Wen XY; Masih-Khan E; Chang H; Pollett JB; Trudel S; Stewart AK
    Br J Haematol; 2004 Mar; 124(5):595-603. PubMed ID: 14871245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model.
    Jonquoy A; Mugniery E; Benoist-Lasselin C; Kaci N; Le Corre L; Barbault F; Girard AL; Le Merrer Y; Busca P; Schibler L; Munnich A; Legeai-Mallet L
    Hum Mol Genet; 2012 Feb; 21(4):841-51. PubMed ID: 22072392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma.
    Hadari Y; Schlessinger J
    J Clin Invest; 2009 May; 119(5):1077-9. PubMed ID: 19422094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.
    Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Nakazawa N; Taniwaki M; Yawata Y; Ueki A
    Int J Oncol; 1999 Dec; 15(6):1205-12. PubMed ID: 10568829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies.
    Chen J; Lee BH; Williams IR; Kutok JL; Mitsiades CS; Duclos N; Cohen S; Adelsperger J; Okabe R; Coburn A; Moore S; Huntly BJ; Fabbro D; Anderson KC; Griffin JD; Gilliland DG
    Oncogene; 2005 Dec; 24(56):8259-67. PubMed ID: 16091734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins.
    Krejci P; Masri B; Salazar L; Farrington-Rock C; Prats H; Thompson LM; Wilcox WR
    J Biol Chem; 2007 Feb; 282(5):2929-36. PubMed ID: 17145761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.
    Trudel S; Li ZH; Wei E; Wiesmann M; Chang H; Chen C; Reece D; Heise C; Stewart AK
    Blood; 2005 Apr; 105(7):2941-8. PubMed ID: 15598814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors.
    Li C; Chen L; Iwata T; Kitagawa M; Fu XY; Deng CX
    Hum Mol Genet; 1999 Jan; 8(1):35-44. PubMed ID: 9887329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor (FGF) 18 signals through FGF receptor 3 to promote chondrogenesis.
    Davidson D; Blanc A; Filion D; Wang H; Plut P; Pfeffer G; Buschmann MD; Henderson JE
    J Biol Chem; 2005 May; 280(21):20509-15. PubMed ID: 15781473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation.
    Chen J; Williams IR; Lee BH; Duclos N; Huntly BJ; Donoghue DJ; Gilliland DG
    Blood; 2005 Jul; 106(1):328-37. PubMed ID: 15784730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.